Navigation Links
UTSW cancer researchers identify irreversible inhibitor for KRAS gene mutation
Date:7/28/2014

DALLAS July 28, 2014 UT Southwestern Medical Center cancer researchers have found a molecule that selectively and irreversibly interferes with the activity of a mutated cancer gene common in 30 percent of tumors.

The molecule, SML-8-73-1 (SML), interferes with the KRAS gene, or Kirsten rat sarcoma viral oncogene homolog. The gene produces proteins called K-Ras that influence when cells divide. Mutations in K-Ras can result in normal cells dividing uncontrollably and turning cancerous. These mutations are particularly found in cancers of the lung, pancreas, and colon. In addition, people who have the mutated gene are less responsive to therapy.

Researchers have unsuccessfully tried to develop a drug to inhibit K-Ras for some 30 years.

"RAS proteins including KRAS have not been 'druggable' for many decades despite a lot of effort from academia and industry," said senior author Dr. Kenneth Westover, Assistant Professor of Radiation Oncology and Biochemistry, and a member of UT Southwestern's Harold C. Simmons Cancer Center.

"We are exploring irreversible inhibitors as a solution, which we believe may pave the way for the development of KRAS-targeted compounds with therapeutic potential and perhaps compounds that target other RAS family proteins involved in cancer," Dr. Westover said.

Dr. Westover works as both a clinician as a member of the Lung Radiation Oncology Team at the Simmons Cancer Center, and as a researcher. The Westover laboratory investigates the molecular basis of cancer with an eye toward developing compounds that perturb cancer biology, and therefore have potential to become therapies. Dr. Westover's lab has been particularly targeting KRAS because this gene is the most commonly mutated oncogene in cancer.

Building on previous work, Dr. Westover and fellow investigators used a technique called X-ray crystallography to determine what happens when SML is added to KRAS carrying the G12C mutation, a hallmark of tobacco-associated lung cancer and present in 25,000 of the new cases of lung cancer in the U.S. annually.

Researchers found that SML irreversibly binds to mutated KRAS, making the KRAS G12C inactive. SML competes with molecules that KRAS naturally binds to, called GTP and GDP, and is not removable, even when GTP and GDP are present at very high levels. This attribute is what makes SML an irreversible inhibitor neither GDP nor GTP are able to knock it off and take its place.

The researchers then used a technique called mass spectrometry to determine that SML is not only irreversible, but selective binding only to KRAS and not the roughly 100 other members of the RAS protein family that have very similar structures.

"We believe SML may be the first irreversible and selective inhibitor of KRAS," said Dr. Westover, who was recruited to UT Southwestern with funds from the state-funded Cancer Research and Prevention Institute of Texas. "As a next step, we are improving the SML compound to facilitate studies involving living cancer cells, and eventually animals and humans."


'/>"/>

Contact: Russell Rian
russell.rian@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert  

Related medicine news :

1. Study helps compare risks of treatments for early esophageal cancer
2. Unhealthy Habits More than Double Risk of Metabolic Syndrome in Childhood Cancer Survivors
3. Potential universal blood test for cancer discovered
4. Healthy Habits May Help Childhood Cancer Survivors Avoid Chronic Ills
5. Lifestyle choices may affect the long-term heart health of childhood cancer survivors
6. Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk
7. Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening
8. Anal, Throat Cancers on the Rise Among Young Adults, Study Finds
9. Scientists test nanoparticle alarm clock to awaken immune systems put to sleep by cancer
10. ACR statement on cancer study regarding patient anxiety from CT lung cancer screening
11. Is Europe putting cancer research at risk?
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UTSW cancer researchers identify irreversible inhibitor for KRAS gene mutation
(Date:9/20/2017)... NC (PRWEB) , ... September 20, 2017 , ... ... Transformation and Centers of Excellence (CoE) with the latest Artificial Intelligence (AI) thinking, ... designed presence offers quick and easy access to essential information that offers a ...
(Date:9/20/2017)... GLENDALE, Calif. (PRWEB) , ... September 20, 2017 ... ... 15th year of providing a voice for people who have kidney disease. The ... many writers to share their stories. Entrants needed to meet only one ...
(Date:9/20/2017)... ... 2017 , ... Mirror Mirror Beauty Boutique is excited to ... Autumn with CoolSculpting®. Scheduled for Thursday, September 28th, the afternoon will include live ... Boutique is Houston’s largest CoolSculpting provider, holding the prestigious title of ...
(Date:9/20/2017)... ... 20, 2017 , ... As part of The Garland Company, ... redesigned website. The new site – still located at http://www.garlandco.com – ... other industry users that Garland serves. , After an ambitious phase of industry ...
(Date:9/20/2017)... ... September 20, 2017 , ... In just a short time since going ... receiving positive feedback from customers trying the product for the first time, and others ... was developed by neurosurgeon Shawn Moore, MD, for everyone from athletes at risk from ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... Sept. 6, 2017  Medical professionals are ... skills while treating their patients. Medical simulations ... without involving patients. Simulation provides a safe ... carry out procedures, refine techniques and build ... of new technology, such as augmented reality, ...
(Date:9/5/2017)... Sapheneia and Scannerside received FDA 510(k) clearance ... a third-party Vendor neutral CT product that makes it ... with current MITA standards. ... is specifically designed to provide CT operators, prior to ... over a predefined threshold. Scannerside Dose Check is intended ...
(Date:9/5/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... focused on the development of oral drug delivery systems, ... with the U.S. Food and Drug Administration (FDA) regarding ... At the meeting, the FDA ... of ORMD-0801, would be a Biologics License Application (BLA).  ...
Breaking Medicine Technology: